Rhythm Biosciences Limited (ASX:RHY)

Market Cap	73.67M +205.6%
Revenue (ttm)	1.65M -48.0%
Net Income	-6.68M
EPS	-0.02
Shares Out	327.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	442,428
Average Volume	1,503,669
Open	0.2300
Previous Close	0.2250
Day's Range	0.2200 - 0.2300
52-Week Range	0.0470 - 0.2800
Beta	0.31
RSI	57.93
Earnings Date	Feb 18, 2026

About Rhythm Biosciences

Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia and the United States. It offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. The company was incorporated in 2017 and is headquartered in Parkville, Australia.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RHY

Financial Performance

In fiscal year 2025, Rhythm Biosciences's revenue was 3.19 million, an increase of 88.85% compared to the previous year's 1.69 million. Losses were -3.83 million, -44.15% less than in 2024.